ImmunityBio proposes 560,000-share sale: what it means for ImmunityBio stock

Published on 10/06/2026 at 06:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A 560,000-share sale was proposed on October 5, 2026. For ImmunityBio stock this means USD 50.7 million in second-quarter revenue, up 92 percent.

IBRX, US45256X1037, Illustration mit AI erstellt.

ImmunityBio (ISIN US45256X1037) disclosed a proposed sale of 560,000 common shares by officer and director Barry J. Simon, with an aggregate value of USD 7.66 million and an approximate sale date of October 5, 2026, according to StockTitan. The filing identifies Nasdaq as the exchange and lists Simon as both an officer and a director.

What the filing means for ImmunityBio

The proposed transaction covers 560,000 shares out of 1,059,836,273 shares outstanding in the filing. Its stated aggregate value is USD 7.66 million, while the filing records the securities as common shares acquired from the issuer through an open-market transaction dated December 31, 2013.

The filing is a proposed sale notice rather than evidence that the transaction has been completed. That distinction matters because the document reports an intended sale date and the number of shares offered, not a final execution price or completed transaction.

Revenue growth meets a wider loss

According to ImmunityBio in its August 4, 2026 release, second-quarter 2026 net product revenue reached USD 50.70 million, up 92.00 percent from the second quarter of 2025. First-half 2026 net product revenue totaled USD 94.80 million, up 121.00 percent year over year.

The standardized second-quarter 2026 income statement shows total revenue of USD 51.24 million and a consolidated net loss of USD 230.39 million, compared with USD 44.21 million of revenue and a USD 632.80 million loss in the first quarter of 2026. Diluted earnings per share were negative USD 0.22 in the second quarter.

Nasdaq listing and product strategy

A master-data profile identifies ImmunityBio as a Nasdaq-listed biotechnology company with ticker IBRX and ISIN US45256X1037. The company develops immunotherapies and vaccines intended to activate the immune system against cancer and infectious diseases, with ANKTIVA as its lead commercial product.

The investor-relations page identifies ANKTIVA as an FDA-approved immunotherapy for certain patients with non-muscle invasive bladder cancer. That commercial platform links the filing to a company still balancing rapid revenue growth against substantial operating losses.

Prior close remains EUR 9.26

The Lang & Schwarz prior close was EUR 9.26 on October 2, 2026, the last Xetra trading day before the October 5 quote date. The reference data carried no valid October 6 intraday price or daily percentage change.